研究单位：[1]Eli Lilly and Company[2]Kunming Medical College Affiliated First Hospital Kunming,Yunnan,China,650032[3]The First People's Hospital of Yunnan Province Kunming,Yunnan,China,650034[4]The Second Affiliated Hospital of Zhejiang University School of Med Hangzhou,Zhejiang,China,310000[5]First Affiliated Hosp of College of Med,Zhejiang University Hangzhou,Zhejiang,China,310003[6]Sir Run Run Shaw Hospital Hangzhou,Zhejiang,China,310016[7]The Second Affiliated Hospital of Wenzhou Medical College Wenzhou,Zhejiang,China,325027[8]Tongji Hospital of Tongji University Wuhan,China,430030
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.
